Aliases & Classifications for H. Pylori Infection

Aliases & Descriptions for H. Pylori Infection:

Name: H. Pylori Infection 54
Helicobacter Pylori Infection, Susceptibility to 29
H. Pylori Infection, Susceptibility to 13
Helicobacter Pylori Infections 41
Helicobacter Pylori Infection 69

Classifications:



External Ids:

OMIM 54 600263

Summaries for H. Pylori Infection

MedlinePlus : 41 helicobacter pylori (h. pylori) is a type of bacteria that causes infection in the stomach. it is found in about two-thirds of the world's population. it may be spread by unclean food and water, but researchers aren't sure. it causes peptic ulcers and can also cause stomach cancer. if you have symptoms of a peptic ulcer, your doctor will test your blood, breath or stool to see if it contains h. pylori. the best treatment is a combination of antibiotics and acid-reducing medicines. you will need to be tested after treatment to make sure the infection is gone. to help prevent an h. pylori infection, you should wash your hands after using the bathroom and before eating eat properly prepared food drink water from a clean, safe source nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : H. Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to gastric cancer risk after h. pylori infection and peptic ulcer disease, and has symptoms including helicobacter pylori infection, abdominal pain and constipation. An important gene associated with H. Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Degradation of the extracellular matrix. The drugs Amoxicillin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and colon, and related phenotypes are cardiovascular system and homeostasis/metabolism

OMIM : 54 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately... (600263) more...

Related Diseases for H. Pylori Infection

Diseases related to H. Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
id Related Disease Score Top Affiliating Genes
1 gastric cancer risk after h. pylori infection 12.2
2 peptic ulcer disease 11.4
3 gastric cancer 10.4
4 gastritis 10.3
5 diphallia 10.2 CDH1 IL1B
6 duodenitis 10.2
7 ileocolitis 10.2 CDH1 IL1B
8 hepatocellular carcinoma 10.2 CDH1 IL1B
9 duodenal ulcer 10.2
10 lacrimal apparatus disease 10.2 CYP2C19 IL1B
11 angiomyoma 10.2 MMP3 TIMP1
12 right atrium familial dilatation 10.1 MMP3 MMP9
13 amyotrophic lateral sclerosis type 14 10.1 CDH1 IL1B
14 benign focal seizures of adolescence 10.1 MMP7 TIMP1
15 esophageal neuroendocrine tumor 10.1 CDH1 PTGS2 TIMP1
16 systemic scleroderma 10.1 MMP3 PTGS2
17 central nervous system adult germ cell tumor 10.1 MMP3 MMP9
18 congenital hypomyelination neuropathy 10.1 MMP9 TIMP1
19 cellulitis 10.1 MMP3 MMP9
20 toxic optic neuropathy 10.1 IL1B MMP9
21 nasal cavity cancer 10.1 CYP2C19 IL1B PTGS2
22 childhood central nervous system mixed germ cell tumor 10.1 CYP2C19 IL1B PTGS2
23 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.1 CYP2C19 IL1B PTGS2
24 conjunctival concretion 10.1 CYP2C19 IL1B PTGS2
25 dyspepsia 10.1
26 acute tricyclic antidepressant poisoning 10.1 MMP7 MMP9
27 autoimmune polyendocrine syndrome type 1 10.1 MMP9 TIMP1
28 immune system disease 10.1 IL1B MMP3 PTGS2
29 adult neuronal ceroid lipofuscinosis 10.1 CDH1 MMP9 PTGS2
30 appendix carcinoid tumor 10.1 MMP9 TIMP1
31 hidradenitis 10.1 IL1B PTGS2
32 keratoconus 10.1 IL1B MMP3 TIMP1
33 senile atrophy of choroid 10.1 MMP7 MMP9
34 mucositis 10.0
35 gastric ulcer 10.0
36 gastroduodenitis 10.0
37 tinea profunda 10.0 MMP7 MMP9
38 ornithinemia 10.0 CDH1 MMP9 PTGS2
39 brain meningioma 10.0 MMP7 MMP9
40 idiopathic corneal edema 10.0 IL1B MMP3
41 in situ pulmonary adenocarcinoma 10.0 CDH1 MMP9 PTGS2
42 malignant pleural solitary fibrous tumor 10.0 CDH1 MMP9 PTGS2
43 maxillary neoplasm 10.0 CDH1 MMP9 TIMP1
44 breast papillary carcinoma 10.0 CDH1 MMP9 TIMP1
45 placenta praevia 10.0 CDH1 MMP9 PTGS2
46 penis agenesis 10.0 MMP7 MMP9
47 nodular cutaneous amyloidosis 10.0 CDH1 MMP9 TIMP1
48 striated muscle rhabdoid tumor 10.0 MMP9 TIMP1
49 lymphoma 10.0
50 adenocarcinoma 10.0

Graphical network of the top 20 diseases related to H. Pylori Infection:



Diseases related to H. Pylori Infection

Symptoms & Phenotypes for H. Pylori Infection

Symptoms by clinical synopsis from OMIM:

600263

Clinical features from OMIM:

600263

Human phenotypes related to H. Pylori Infection:

32
id Description HPO Frequency HPO Source Accession
1 helicobacter pylori infection 32 HP:0005202

UMLS symptoms related to H. Pylori Infection:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, icterus, nausea and vomiting, pruritus, gastrointestinal gas

MGI Mouse Phenotypes related to H. Pylori Infection:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.98 CDH1 IFNGR1 IL1B MMP7 MMP9 PTGS2
2 homeostasis/metabolism MP:0005376 9.92 CDH1 IFNGR1 IL1B MMP3 MMP7 MMP9
3 hematopoietic system MP:0005397 9.91 IFNGR1 IL1B MMP3 MMP7 MMP9 PTGS2
4 immune system MP:0005387 9.91 CDH1 IFNGR1 IL1B MMP3 MMP7 MMP9
5 digestive/alimentary MP:0005381 9.8 CDH1 IFNGR1 MMP7 MMP9 PTGS2
6 integument MP:0010771 9.63 CDH1 IFNGR1 IL1B MMP9 PTGS2 PTPRZ1
7 neoplasm MP:0002006 9.5 CDH1 IFNGR1 IL1B MMP7 MMP9 PTGS2
8 skeleton MP:0005390 9.1 IL1B MMP3 MMP9 PTGS2 TIMP1 IFNGR1

Drugs & Therapeutics for H. Pylori Infection

Drugs for H. Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 26787-78-0 33613 2171
2
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
3
Guaifenesin Approved, Vet_approved Phase 4,Phase 3 93-14-1 3516
4
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1 443-48-1 4173
5
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3 117976-89-3 5029
6
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
7
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 103577-45-3 3883
8
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
9
Tetracycline Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 60-54-8 5353990
10
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2 161796-78-7, 119141-88-7 4594 9579578
11
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
12
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
13
Pantoprazole Approved Phase 4,Phase 2,Phase 3 102625-70-7 4679
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757 53477783
15
Ethinyl Estradiol Approved Phase 4,Phase 3 57-63-6 5991
16
Moxifloxacin Approved, Investigational Phase 4,Phase 3 354812-41-2, 151096-09-2 152946
17
Norgestimate Approved Phase 4,Phase 3 35189-28-7 6540478
18
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
19 Titanium dioxide Approved Phase 4 13463-67-7
20
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2 19387-91-8 5479
21
Coal tar Approved Phase 4 8007-45-2
22
Bismuth Subsalicylate Approved, Vet_approved Phase 4,Phase 3,Phase 2 14882-18-9 53629521
23
Loperamide Approved Phase 4,Phase 3,Phase 2 53179-11-6 3955
24
Potassium Citrate Approved, Vet_approved Phase 4,Phase 3
25
Menthol Approved Phase 4 2216-51-5 16666
26
Furazolidone Approved, Vet_approved Phase 4,Phase 2,Phase 3 67-45-8 3435 5323714
27
Azithromycin Approved Phase 4,Phase 3 83905-01-5 55185 53477736 447043
28
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
29
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 3 55981-09-4 41684
30
Pancrelipase Approved Phase 4 53608-75-6
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 564-25-0 54671203
32
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
33
Vitamin C Approved, Nutraceutical Phase 4,Phase 3 50-81-7 5785 54670067
34
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
35 Antacids Phase 4,Phase 2,Phase 3,Phase 1
36 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
37 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
38 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3
43 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
44 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
45 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
46
Proton pump inhibitors Phase 4,Phase 2,Phase 3,Phase 1
47 Antidotes Phase 4
48 Antioxidants Phase 4
49 Antiviral Agents Phase 4
50
Dexlansoprazole Phase 4,Phase 3,Phase 2 138530-94-6, 103577-45-3 9578005

Interventional clinical trials:

(show top 50) (show all 297)
id Name Status NCT ID Phase
1 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4
2 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4
3 H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study Unknown status NCT01335334 Phase 4
4 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4
5 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4
6 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4
7 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4
8 Antimicrobial Susceptibility for Helicobacter Pylori Eradication Unknown status NCT01486082 Phase 4
9 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4
10 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy Unknown status NCT01537055 Phase 4
11 Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy Unknown status NCT01607918 Phase 4
12 Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy Unknown status NCT01572597 Phase 4
13 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4
14 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4
15 Helicobacter Pylori Empiric Treatment in Ulcer Bleeding Unknown status NCT00687336 Phase 4
16 Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection Completed NCT01769365 Phase 4
17 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4
18 Sequential and Hybrid Therapies for H Pylori Infection Completed NCT01085786 Phase 4
19 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4
20 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4
21 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4
22 15-day Sequential Therapy for Helicobacter Pylori Infection in Korea Completed NCT01887249 Phase 4
23 Efficacy and Safety of Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
24 A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4
25 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection Completed NCT00854451 Phase 4
26 Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Completed NCT02711176 Phase 4
27 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection Completed NCT02401477 Phase 4
28 Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori Completed NCT01042184 Phase 4
29 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4
30 Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT01742429 Phase 4
31 High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4
32 RCT: Triple vs Sequential vs Concomitant Therapy H Pylori Completed NCT02092506 Phase 4
33 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) Completed NCT00825630 Phase 4
34 Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults. Completed NCT00216450 Phase 4
35 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4
36 Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori Completed NCT03108287 Phase 4
37 Clarithromycin Resistant Tailored Therapy Completed NCT01453036 Phase 4
38 Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients Completed NCT02466919 Phase 4
39 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4
40 Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori Completed NCT01573975 Phase 4
41 POCone-UBiT-IR300 Pediatric Comparison Study Completed NCT01623154 Phase 4
42 Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori Completed NCT02352701 Phase 4
43 Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication Completed NCT01163435 Phase 4
44 Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication Completed NCT00841854 Phase 4
45 Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication Completed NCT00816140 Phase 4
46 Eradication Rates of Helicobacter Pylori and Its Affecting Factors Completed NCT01922505 Phase 4
47 Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy Completed NCT01792700 Phase 4
48 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4
49 Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens Completed NCT02395458 Phase 4
50 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4

Search NIH Clinical Center for H. Pylori Infection

Genetic Tests for H. Pylori Infection

Genetic tests related to H. Pylori Infection:

id Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 29

Anatomical Context for H. Pylori Infection

MalaCards organs/tissues related to H. Pylori Infection:

39
Testes, Kidney, Colon, T Cells, Brain, Neutrophil, Liver

Publications for H. Pylori Infection

Articles related to H. Pylori Infection:

(show top 50) (show all 336)
id Title Authors Year
1
Association of H. pylori infection with chronic kidney disease among Chinese adults. ( 28044235 )
2017
2
The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta-analysis. ( 28353592 )
2017
3
The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. ( 28079669 )
2017
4
Interaction of Ethnicity and H. pylori Infection in the Occurrence of Microscopic Colitis. ( 28070826 )
2017
5
Diagnostic accuracy of nodular gastritis for H. pylori infection. ( 28031716 )
2017
6
Clinical Outcome of Eradication Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to H. pylori Infection Status. ( 27034656 )
2016
7
Cdx2 Expression and Intestinal Metaplasia Induced by H. pylori Infection of Gastric Cells Is Regulated by NOD1-Mediated Innate Immune Responses. ( 26759244 )
2016
8
Downregulated Expression of E-cadherin and TP53 in Patients with Gastric Diseases: the Involvement of H. pylori Infection and Its Virulence Markers. ( 26585943 )
2016
9
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. ( 26875899 )
2016
10
Celiac Disease and H. Pylori Infection in Children: Is there any Association? ( 27862319 )
2016
11
Real-time diagnosis of H. pylori infection during endoscopy: Accuracy of an innovative tool (EndoFaster). ( 27403299 )
2016
12
Molecular Mechanisms of Natural Honey Against H. pylori Infection Via Suppression of NF-I_B and AP-1 Activation in Gastric Epithelial Cells. ( 27751367 )
2016
13
Central Obesity and H. pylori Infection Influence Risk of Barrett's Esophagus in an Asian Population. ( 27936223 )
2016
14
H. PYLORI INFECTION, ENDOSCOPIC, HISTOLOGICAL ASPECTS AND CELL PROLIFERATION IN THE GASTRIC MUCOSA OF PATIENTS SUBMITTED TO ROUX-EN-Y GASTRIC BYPASS WITH CONTENTION RING: a cross sectional endoscopic and immunohistochemical study. ( 27281506 )
2016
15
H. pylori infection is related to mitochondrial microsatellite instability in gastric carcinogenesis. ( 27408617 )
2016
16
Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanelAr) in St. Petersburg. ( 27466521 )
2016
17
Diagnosis and Treatment of Peptic Ulcer Disease and H. pylori Infection. ( 25955624 )
2015
18
Effect of ERCC8 tagSNPs and their association with H. pylori infection, smoking, and alcohol consumption on gastric cancer and atrophic gastritis risk. ( 26130415 )
2015
19
Inflammation and proliferation- A causal event of host response to H. pylori infection. ( 25721850 )
2015
20
Effect of H. pylori infection on gastrin, ghrelin, motilin, and gastroesophageal reflux. ( 26350687 )
2015
21
Genomic single nucleotide polymorphisms in the offspring of gastric cancer patients predispose to spasmolytic polypeptide-expressing metaplasia after H. pylori infection. ( 25884934 )
2015
22
Diagnostic methods for H. pylori infection: Choices, opportunities and pitfalls. ( 26535120 )
2015
23
Chronic Gastritis and its Association with H. Pylori Infection. ( 26620009 )
2015
24
Telomere length in non-neoplastic gastric mucosa and its relationship to H. pylori infection, degree of gastritis, and NSAID use. ( 25563818 )
2015
25
Occult H. pylori infection partially explains 'false-positive' results of (13)C-urea breath test. ( 26535122 )
2015
26
Effects of H. pylori infection on carotid intima-media thickness, serum glucose, serum uric acid, liver and kidney function in subjects with chronic alcohol ingestion. ( 25846655 )
2015
27
PP-7 CHILDHOOD RECURRENT ABDOMINAL PAIN IS ASSOCIATED WITH DUODENAL EOSINOPHILIA REGARDLESS OF H. PYLORI INFECTION. ( 26439572 )
2015
28
Coenzyme q10 in combination with triple therapy regimens ameliorates oxidative stress and lipid peroxdiation in chronic gastritis associated with H. pylori infection. ( 25854786 )
2015
29
The role of H. pylori infection in gall bladder cancer: clinicopathological study. ( 25877756 )
2015
30
Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between H. pylori Infection and Low-Dose Aspirin Use. ( 26369687 )
2015
31
Effect of H. pylori Infection on Cytokine Profiles and Oxidative Balance in Subjects with Chronic Alcohol Ingestion. ( 26087062 )
2015
32
Sequential or concomitant therapy for eradication of H. pylori infection: a systematic review and meta-Analysis. ( 25867718 )
2015
33
Comparative Immune Response in Children and Adults with H. pylori Infection. ( 26495322 )
2015
34
Effects of the interleukin-1I^-511 C/T gene polymorphism on the risk of gastric cancer in the context of the relationship between race and H. pylori infection: a meta-analysis of 20,000 subjects. ( 25258120 )
2014
35
The Relationship between H. pylori Infection and Osteoporosis in Japan. ( 25024699 )
2014
36
CYP2E1 Genetic Polymorphism with Dietary, Tobacco, Alcohol Habits, H. pylori Infection Status and Susceptibility to Stomach Cancer in Mizoram, India. ( 25374213 )
2014
37
H. pylori infection, inflammation and gastric cancer. ( 24557546 )
2014
38
Standard therapeutic regimens in H. pylori infection leads to activation of transitory fungal flora in gastric mucus. ( 25518495 )
2014
39
Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. ( 24633026 )
2014
40
Helicobacter-negative gastritis: a distinct entity unrelated to H. pylori infection. ( 25376264 )
2014
41
Letter: Bismuth quadruple therapy with Pylera for H. pylori infection. ( 25123391 )
2014
42
Community-driven research on environmental sources of H. pylori infection in arctic Canada. ( 25483330 )
2014
43
ABCB1 expression in peptic ulcer patients and its connection with H. pylori Infection. ( 25117101 )
2014
44
Whole-miRNome profiling identifies prognostic serum miRNAs in esophageal adenocarcinoma: the influence of H. pylori infection status. ( 25381453 )
2014
45
Antibiotics resistance of Helicobacter pylori and treatment modalities in children with H. pylori infection. ( 24678329 )
2014
46
Does tonsillectomy affect the outcome of drug treatment for the eradication of gastric H pylori infection? A pilot study. ( 23532649 )
2013
47
Defining the role of sequential therapy for H pylori infection. ( 23158881 )
2013
48
Interaction among Caveolin-1 genotypes (rs3807987/rs7804372), H. pylori infection, and risk of gastric cancer in a Chinese population. ( 24065198 )
2013
49
Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection. ( 24126798 )
2013
50
Prevalence of and risk factors for H. pylori infection in healthy children and young adults in Belgium anno 2010/2011. ( 24592540 )
2013

Variations for H. Pylori Infection

ClinVar genetic disease variations for H. Pylori Infection:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 IFNGR1 IFNGR1, -56C-T single nucleotide variant protective,risk factor

Expression for H. Pylori Infection

LifeMap Discovery
Genes differentially expressed in tissues of H. Pylori Infection patients vs. healthy controls: 35 (show top 50) (show all 94)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FDCSP follicular dendritic cell secreted protein "Gastrointestinal Tract,Stomach" + 9.19 0.000
2 DMBT1 deleted in malignant brain tumors 1 "Gastrointestinal Tract,Stomach" + 7.69 0.000
3 REG3G regenerating islet-derived 3 gamma "Gastrointestinal Tract,Stomach" + 6.56 0.000
4 CR2 complement component (3d/Epstein Barr virus) receptor 2 "Gastrointestinal Tract,Stomach" + 6.52 0.000
5 OLFM4 olfactomedin 4 "Gastrointestinal Tract,Stomach" + 6.34 0.001
6 CXCL13 chemokine (C-X-C motif) ligand 13 "Gastrointestinal Tract,Stomach" + 6.24 0.000
7 REG3A regenerating islet-derived 3 alpha "Gastrointestinal Tract,Stomach" + 6.15 0.000
8 CD19 CD19 molecule "Gastrointestinal Tract,Stomach" + 5.25 0.000
9 FCRL3 Fc receptor-like 3 "Gastrointestinal Tract,Stomach" + 5.18 0.000
10 CXCR5 chemokine (C-X-C motif) receptor 5 "Gastrointestinal Tract,Stomach" + 5.12 0.000
11 SAA2 serum amyloid A2 "Gastrointestinal Tract,Stomach" + 4.81 0.000
12 MS4A1 membrane-spanning 4-domains, subfamily A, member 1 "Gastrointestinal Tract,Stomach" + 4.76 0.000
13 CCL20 chemokine (C-C motif) ligand 20 "Gastrointestinal Tract,Stomach" + 4.64 0.000
14 ABCA12 ATP-binding cassette, sub-family A (ABC1), member 12 "Gastrointestinal Tract,Stomach" + 4.60 0.000
15 SAA1 serum amyloid A1 "Gastrointestinal Tract,Stomach" + 4.59 0.000
16 NLRP7 NLR family, pyrin domain containing 7 "Gastrointestinal Tract,Stomach" + 4.56 0.000
17 CCL19 chemokine (C-C motif) ligand 19 "Gastrointestinal Tract,Stomach" + 4.52 0.000
18 VNN1 vanin 1 "Gastrointestinal Tract,Stomach" + 4.51 0.000
19 BPIFB1 BPI fold containing family B, member 1 "Gastrointestinal Tract,Stomach" + 4.48 0.000
20 AFAP1-AS1 AFAP1 antisense RNA 1 "Gastrointestinal Tract,Stomach" + 4.47 0.000
21 CCR7 chemokine (C-C motif) receptor 7 "Gastrointestinal Tract,Stomach" + 4.38 0.000
22 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) "Gastrointestinal Tract,Stomach" + 4.33 0.000
23 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) "Gastrointestinal Tract,Stomach" + 4.30 0.000
24 DEFB4A defensin, beta 4A "Gastrointestinal Tract,Stomach" + 4.25 0.000
25 LAIR2 leukocyte-associated immunoglobulin-like receptor 2 "Gastrointestinal Tract,Stomach" + 4.22 0.000
26 TCL1A T-cell leukemia/lymphoma 1A "Gastrointestinal Tract,Stomach" + 4.16 0.000
27 SELL selectin L "Gastrointestinal Tract,Stomach" + 4.14 0.000
28 S100A8 S100 calcium binding protein A8 "Gastrointestinal Tract,Stomach" + 4.09 0.000
29 FCRL5 Fc receptor-like 5 "Gastrointestinal Tract,Stomach" + 3.95 0.000
30 TLR10 toll-like receptor 10 "Gastrointestinal Tract,Stomach" + 3.95 0.000
31 C3 complement component 3 "Gastrointestinal Tract,Stomach" + 3.95 0.000
32 LCN2 lipocalin 2 "Gastrointestinal Tract,Stomach" + 3.92 0.000
33 MMP7 matrix metallopeptidase 7 "Gastrointestinal Tract,Stomach" + 3.88 0.000
34 CD28 CD28 molecule "Gastrointestinal Tract,Stomach" + 3.80 0.000
35 BLK BLK proto-oncogene, Src family tyrosine kinase "Gastrointestinal Tract,Stomach" + 3.80 0.000
36 CD22 CD22 molecule "Gastrointestinal Tract,Stomach" + 3.80 0.000
37 FCRL2 Fc receptor-like 2 "Gastrointestinal Tract,Stomach" + 3.78 0.000
38 CXCL8 chemokine (C-X-C motif) ligand 8 "Gastrointestinal Tract,Stomach" + 3.77 0.000
39 FCRL4 Fc receptor-like 4 "Gastrointestinal Tract,Stomach" + 3.72 0.000
40 CXCL2 chemokine (C-X-C motif) ligand 2 "Gastrointestinal Tract,Stomach" + 3.69 0.000
41 CD180 CD180 molecule "Gastrointestinal Tract,Stomach" + 3.68 0.000
42 PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) "Gastrointestinal Tract,Stomach" + 3.66 0.000
43 FCAMR Fc receptor, IgA, IgM, high affinity "Gastrointestinal Tract,Stomach" + 3.65 0.000
44 AQP9 aquaporin 9 "Gastrointestinal Tract,Stomach" + 3.64 0.000
45 FCRLA Fc receptor-like A "Gastrointestinal Tract,Stomach" + 3.63 0.000
46 AIM2 absent in melanoma 2 "Gastrointestinal Tract,Stomach" + 3.63 0.000
47 LTF lactotransferrin "Gastrointestinal Tract,Stomach" + 3.63 0.000
48 KRT6B keratin 6B, type II "Gastrointestinal Tract,Stomach" + 3.60 0.000
49 C6 complement component 6 "Gastrointestinal Tract,Stomach" - 3.60 0.000
50 NEURL3 neuralized E3 ubiquitin protein ligase 3 "Gastrointestinal Tract,Stomach" + 3.59 0.000
Search GEO for disease gene expression data for H. Pylori Infection.

Pathways for H. Pylori Infection

Pathways related to H. Pylori Infection according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 IFNGR1 IL1B MMP3 MMP9 PTGS2 TIMP1
2
Show member pathways
12.53 CDH1 MMP3 MMP7 MMP9 TIMP1
3
Show member pathways
12.14 IL1B MMP3 MMP9 PTGS2
4
Show member pathways
12.04 IFNGR1 IL1B PTGS2
5
Show member pathways
12.02 IFNGR1 IL1B PTGS2
6 11.81 IL1B MMP9 PTGS2 PTPRZ1
7 11.77 CDH1 MMP3 MMP9
8 11.77 CDH1 IFNGR1 MMP7 MMP9 PTGS2
9 11.74 IL1B MMP3 MMP9 PTGS2
10
Show member pathways
11.66 MMP3 MMP7 MMP9 TIMP1
11
Show member pathways
11.61 IFNGR1 IL1B
12 11.5 IL1B MMP9 TIMP1
13
Show member pathways
11.42 IL1B MMP3 MMP9 PTGS2
14 11.41 IL1B MMP3 MMP9 PTGS2 TIMP1
15 11.36 IL1B PTGS2 TIMP1
16 11.34 MMP3 MMP7 MMP9 TIMP1
17 11.18 MMP3 MMP9
18 11.15 IFNGR1 IL1B
19 11.03 IL1B MMP9 TIMP1
20 10.96 MMP3 MMP7 MMP9 PTGS2 TIMP1
21 10.79 MMP7 MMP9

GO Terms for H. Pylori Infection

Cellular components related to H. Pylori Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CDH1 IL1B MMP3 MMP7 MMP9 PTPRZ1
2 extracellular matrix GO:0031012 9.26 MMP3 MMP7 MMP9 TIMP1
3 proteinaceous extracellular matrix GO:0005578 9.02 MMP3 MMP7 MMP9 PTPRZ1 TIMP1

Biological processes related to H. Pylori Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.61 MMP7 PTGS2 TIMP1
2 response to organic substance GO:0010033 9.54 CDH1 PTGS2 TIMP1
3 cellular response to mechanical stimulus GO:0071260 9.5 IL1B MMP7 PTGS2
4 positive regulation of nitric oxide biosynthetic process GO:0045429 9.48 IL1B PTGS2
5 positive regulation of vascular endothelial growth factor production GO:0010575 9.46 IL1B PTGS2
6 collagen catabolic process GO:0030574 9.43 MMP3 MMP7 MMP9
7 positive regulation of NF-kappaB import into nucleus GO:0042346 9.4 IL1B PTGS2
8 positive regulation of fever generation GO:0031622 9.16 IL1B PTGS2
9 embryo implantation GO:0007566 9.13 IL1B MMP9 PTGS2
10 extracellular matrix disassembly GO:0022617 9.02 CDH1 MMP3 MMP7 MMP9 TIMP1

Molecular functions related to H. Pylori Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 metallopeptidase activity GO:0008237 9.13 MMP3 MMP7 MMP9
2 metalloendopeptidase activity GO:0004222 8.8 MMP3 MMP7 MMP9

Sources for H. Pylori Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....